Arcutis Biotherapeutics, Inc. Common Stock
ARQT
ARQT: Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's lead product candidate ZORYVE roflumilast cream, has successfully completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
moreShow ARQT Financials
Recent trades of ARQT by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by ARQT's directors and management
Government lobbying spending instances
New patents grants
-
Patent Title: Laureth-4 containing topical formulations Aug. 22, 2023
-
Patent Title: Topical roflumilast formulation having antifungal properties Jul. 25, 2023
-
Patent Title: Compositions and methods for deep dermal drug delivery Apr. 18, 2023
-
Patent Title: Pharmaceutical compositions of roflumilast in aqueous blends of water-miscible, pharmaceutically acceptable solvents Dec. 27, 2022
-
Patent Title: Topical roflumilast formulation having improved delivery and plasma half life Sep. 28, 2021
Federal grants, loans, and purchases
Followers on ARQT's company Twitter account
Number of mentions of ARQT in WallStreetBets Daily Discussion
Recent insights relating to ARQT
Recent picks made for ARQT stock on CNBC
ETFs with the largest estimated holdings in ARQT
Flights by private jets registered to ARQT